



## Michaela Liedtke

CKD Family Professor  
Medicine - Hematology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr Rm 2327

MC 6560

Stanford, CA 94305

Tel (650) 498-6000      Fax (650) 724-5203

### Bio

---

#### CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Hematology > Leukemia - Acute and Chronic
- Multiple Myeloma
- Amyloidosis
- Hematology

#### ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Hematology
- Member, Cardiovascular Institute

#### ADMINISTRATIVE APPOINTMENTS

- Co-Director, Stanford Amyloid Center, (2010- present)
- Member Leukemia Committee, Southwest Oncology Group, (2011- present)
- Medical Director, Stanford Adolescent and Young Adult Program, (2015- present)
- Unit Based Medical Director Inpatient Hematology, Stanford, (2019-2021)
- Cancer Center Program Lead, Hematology, Stanford, (2019- present)

#### HONORS AND AWARDS

- Translational Research Award, Doris Duke Foundation (2004)
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Young Investigator Award, ASCO (2008)

- Translational Research Award, Stanford Department of Medicine (2011)

## **BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS**

- Member, American Society of Hematology (2002 - present)
- Member, American Society of Clinical Oncology (2002 - present)
- Member, International Myeloma Society (2012 - present)
- Member, Association of Northern California Oncologists (2014 - present)
- Member, International Society of Amyloidosis (2016 - present)

## **PROFESSIONAL EDUCATION**

- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Residency: Albert Einstein College of Medicine (2002) NY
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Fellowship: Stanford University Medical Center (2005) CA
- Board Certification: Hematology, American Board of Internal Medicine (2005)

## **LINKS**

- Stanford Amyloid Center: <http://stanfordhospital.org/clinicsmedServices/COE/heart/DiseasesConditions/amyloid/>

## **Research & Scholarship**

---

### **CURRENT RESEARCH AND SCHOLARLY INTERESTS**

- 1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
- 2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
- 3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis

### **CLINICAL TRIALS**

- (QUANTUM-WILD) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD N, Recruiting)
- Phase I First-in-Human Study of Single-Agent ISB 2001 in Relapsed/Refractory Multiple Myeloma, Recruiting
- Phase III Inotuzumab Ozogamicin(Anti-CD22 Mab) vs Frontline Tx in NewlyDiagnosedPrecursor B-Cell ALL, Recruiting
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma, Recruiting
- COVALENT-101: A Phase I FIH BMF-219 Oral Covalent Menin Inhibitor, in AL, DLBCL, MM, CLL, and SLL, Not Recruiting
- Expanded Tx Panobinostat(LBH589)+Bortezomib+Dexamethasone in Relapsed & Refractory Multiple Myeloma, Not Recruiting
- Longterm Follow-up of Subjects Treated with bb2121, Not Recruiting
- Ph 2b NEOD001 in Previously Treated Light Chain (AL) Amyloidosis, Not Recruiting
- Phase 1/1b Bcl-2 Inhibitor BGB-11417 in Mature B-Cell Malignancies, Not Recruiting
- Phase 1/2 NEOD001 in Light Chain (AL) Amyloidosis, Not Recruiting
- Phase I 1st-in-Human BCL-2Inhibitor ABBV-453 in Biomarker-SelectedRelapsed/RefractoryMultipleMyeloma, Not Recruiting
- Phase I ALLO-715 &ALLO-647 Eval Anti-BCMA Allogeneic CAR T Cell Treatment +/- Nirogacestat in R/R MM, Not Recruiting
- Phase I Amrubicin plus Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory MM, Not Recruiting
- Phase I bb2121 in BCMA-Expressing Multiple Myeloma, Not Recruiting

- Phase I Bortezomib (VELCADE) in Combo with Pralatrexate in Relapsed/Refractory MM, Not Recruiting
- Phase I Carfilzomib in Previously-Treated Systemic Light-Chain (AL) Amyloidosis, Not Recruiting
- Phase I CC-98633 BCMA Targeted NEX-T CAR T Cells, in Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- Phase I Inotuzumab Ozogamicin with CVP in Relapsed/Refractory CD22+ Acute Leukemia, Not Recruiting
- Phase I SEA-BCMA in Relapsed or Refractory Multiple Myeloma, Not Recruiting
- Phase I/II AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation, Not Recruiting
- Phase I/II CEP-18770 in Relapsed Multiple Myeloma Refractory to the Most Recent Therapy, Not Recruiting
- Phase I/II Inotuzumab Ozogamicin In Relapsed or Refractory CD22-Positive ALL, Not Recruiting
- Phase I/II MLN9708 +/- Lenalidomide & Dexamethasone in Multiple Myeloma Requiring Systemic Treatment, Not Recruiting
- Phase IB BET Inhibitor RO6870810 - Given as Mono & Combination Therapy in Advanced Multiple Myeloma, Not Recruiting
- Phase Ib/II Entospletinib +Vincristine &Dexamethasone in Relapsed /Refractory ALL, Not Recruiting
- Phase II CAEL-101 in AL Amyloidosis, Not Recruiting
- Phase II Daratumumab Pomalidomide & Dexamethasone in Relapsed/Refractory Light Chain Amyloidosis, Not Recruiting
- Phase II Dasatinib Followed by Transplantation in Newly Diagnosed Ph+ ALL, Not Recruiting
- Phase II Extension NEOD001 in Light Chain (AL) Amyloidosis, Not Recruiting
- Phase II Hyper-CVAD + Dasatinib +/- Allogeneic Stem Cell Transplant in Ph Chromosome + and/or ALL , Not Recruiting
- Phase II Idarubicin & Ara-C +/- Pravastatin in Poor-Risk Acute Myelogenous Leukemia(AML) , Not Recruiting
- Phase II Inotuzumab +Chemo vs Standard Chemo in Philadelphia-Chromosome-Negative B-Cell ALL, Not Recruiting
- Phase II Intergroup Clinical Trial For Adolescents & Young Adults With Untreated ALL, Not Recruiting
- Phase II Magrolimab Combinations in Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Phase II Subcutaneous Bortezomib plus Chemo (VXLD) in Relapsed/Refractory ALL, Not Recruiting
- Phase III bb2121 vs Standard Regimens in Relapsed & Refractory Multiple Myeloma (RRMM) (KarMMA-3), Not Recruiting
- Phase III Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage ALL, Not Recruiting
- Phase III CAEL-101 &PCD Tx vs Placebo &PCD Tx in PCD Tx-Naive w/ Mayo Stage IIIa AL Amyloidosis, Not Recruiting
- Phase III CAEL-101 &PCD Tx vs Placebo &PCD Tx in PCD Tx-Naive w/ Mayo Stage IIIb AL Amyloidosis, Not Recruiting
- Phase III Consolidation with VRD vs VD in MM after Dexamethasone Based Induction Tx, Not Recruiting
- Phase III CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Vs Cytarabine & Daunorubicin in AML, Not Recruiting
- Phase III Cyclophosphamide Bortezomib Dexamethasone +/- Daratumumab in Systemic AL Amyloidosis, Not Recruiting
- Phase III Inotuzumab Ozogamicin vs Defined Investigator's Choice in Relapsed/Refractory CD22+ ALL, Not Recruiting
- Phase III NEOD001 + SoC vs Placebo + SoC in Light Chain (AL) Amyloidosis, Not Recruiting
- Phase III RVD versus RVD plus auto SCT in newly diagnosed Multiple Myeloma, Not Recruiting
- Connect MM: The Multiple Myeloma Disease Registry, Not Specified

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

## Publications

### PUBLICATIONS

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*  
Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al  
2026
- **Hepatic response criteria in light chain amyloidosis: a multicenter validation study.** *Haematologica*  
Mughtar, E., Palladini, G., Schonland, S., Geyer, S., Dooley, K. E., Dispenzieri, A., Wisniewski, B., Merlini, G., Milani, P., Hegenbart, U., Dittrich, T., Kastiris, E., Dimopoulos, et al  
2026
- **Multiple Myeloma, Version 5.2026** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D'angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, et al  
2026; 24 (1)
- **Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE** *CLINICAL MEDICINE INSIGHTS-CARDIOLOGY*  
Nativi-Nicolau, J., Fajardo, J., Galloway, A., Khella, S., Kumar, N., Liedtke, M., Lousada, I., Patrick, T., Moffitt, C., Klein, L., Tamariz, G., Veeraraghavalu, K., Haddad-Angulo, et al  
2026; 20
- **Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL.** *Blood advances*  
Anderson, D. R., Gangaraju, R., Sedhom, W. G., Hamulyák, E. N., Wang, T. F., O'Dwyer, K. M., Carney, B. J., Muthiah, C., Liedtke, M., Badar, T., Shimony, S., Robinson, R., Sanfilippo, et al  
2025
- **Real-world performance of the CALGB 10403 regimen in young adults in the United States.** *Blood neoplasia*  
DaSilva, B., Darwin, A., Zhang, A., Vyas, R. D., Russell, K., Gilbert, J. S., Tan, V., Feldt, S., Johnston, H., Liang, E. C., DuVall, A. S., Liedtke, M., Stock, et al  
2025; 2 (3): 100111
- **Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.** *EJHaem*  
Paul, B., Minarik, J., Cottini, F., Gasparetto, C., Khouri, J., Gandhi, M., Hillengass, J., Levy, M., Liedtke, M., Manda, S., Sandhu, I., Sborov, D., Spicka, et al  
2025; 6 (3): e70072
- **NCCN Guidelines Insights: Multiple Myeloma, Version 1.2025.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, et al  
2025; 23 (5): 132-140
- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*  
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al  
2025; 16 (1): 1824
- **Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.** *Leukemia*  
Ravi, G., Richard, S., Kumar, S., Atrash, S., Liedtke, M., Kaur, G., Derman, B., Bergsagel, P. L., Mailankody, S., McCarthy, P., Shrestha, A., Kelly, L. M., Ly, et al  
2025
- **MGCS: where do we stand today?** *Hematology. American Society of Hematology. Education Program*  
Ibberri, D., Liedtke, M.  
2024; 2024 (1): 482-488

- **Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Shah, B., Mattison, R. J., Abboud, R., Abdelmessieh, P., Aldoss, I., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Haddadin, M., Jain, N., Jonas, et al  
2024; 22 (8): 563-576
- **Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.** *JAMA oncology*  
Mughtar, E., Wisniowski, B., Geyer, S., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Leung, N., Dispenzieri, A., Kumar, S. K., Kastritis, et al  
2024
- **Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.** *The New England journal of medicine*  
Litzow, M. R., Sun, Z., Mattison, R. J., Paietta, E. M., Roberts, K. G., Zhang, Y., Racevskis, J., Lazarus, H. M., Rowe, J. M., Arber, D. A., Wieduwilt, M. J., Liedtke, M., Bergeron, et al  
2024; 391 (4): 320-333
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*  
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al  
2024
- **The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.** *Leukemia & lymphoma*  
Palladini, G., Liedtke, M., Zago, W., Dolan, P., Kinney, G. G., Gertz, M. A.  
2024: 1-11
- **Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.** *Blood advances*  
Zhao, Y., Laird, A. D., Roberts, K. G., Yafawi, R. L., Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Göckbuget, N., O'Brien, S. M., Jabbour, E. J., Cassaday, et al  
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*  
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al  
2024
- **Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, et al  
2024; 22 (1D): e240001
- **Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions.** *Journal of adolescent and young adult oncology*  
Jin, A. H., Simon, P. J., Clayton, A., Benedict, C., Liedtke, M., Muffly, L., Schapira, L., Smith, S. M.  
2023
- **Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.** *Nature medicine*  
Lin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Massaro, M., Petrocca, F., Yeri, A., Finney, et al  
2023
- **Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.** *Blood*  
Gertz, M. A., Cohen, A. D., Comenzo, R. L., Kastritis, E., Landau, H. J., Libby, E. N., Liedtke, M., Sanchorawala, V., Schonland, S., Wechalekar, A. D., Zonder, J. A., Palladini, G., Walling, et al  
2023
- **Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.**  
Liedtke, M., Palladini, G., Molina, M., Kastritis, E., Ianus, J., Catini, J., Quarta, C., Wechalekar, A. D., 301 & 302 Investigators  
LIPPINCOTT WILLIAMS & WILKINS.2023

- **Plasma cell leukemia: A multicenter retrospective study of 150 patients.**  
Chineke, I., Wertheim, B. C., Roe, D., Larsen, A., Sborov, D. W., Vardell, V., Green, D., Degraff, D., Liedtke, M., Okoniewski, M., Wazir, M., Nadeem, O., Shubert, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.** *Future oncology (London, England)*  
Paul, B., Liedtke, M., Khouri, J., Rifkin, R., Gandhi, M. D., Kin, A., Levy, M. Y., Silbermann, R., Cottini, F., Sborov, D. W., Sandhu, I., Villarreal, L., Murphy, et al  
2023
- **Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.** *Nature medicine*  
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, et al  
2023
- **Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, et al  
2023; 21 (1): 67-81
- **Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, et al  
2023; 21 (12): 1281-1301
- **Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.** *Seminars in oncology*  
Testa, S., Kumar, J., Goodell, A. J., Zehnder, J. L., Alexander, K. M., Sidana, S., Arai, S., Witteles, R. M., Liedtke, M.  
2022
- **AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review.** *JACC. CardioOncology*  
Wechalekar, A. D., Fontana, M., Quarta, C. C., Liedtke, M.  
2022; 4 (4): 427-441
- **Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.** *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*  
Dispenzieri, A., Zonder, J., Hoffman, J., Wong, S. W., Liedtke, M., Abonour, R., D'Souza, A., Lee, C., Cote, S., Pottluri, R., Ammann, E., Tran, N., Lam, et al  
2022: 1-8
- **The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study.** *Blood advances*  
Aldoss, I., Yin, J., Wall, A., Mrozek, K., Liedtke, M., Claxton, D., Foster, M. C., Appelbaum, F. R., Erba, H. P., Litzow, M. R., Tallman, M. S., Stone, R. M., Larson, et al  
2022
- **Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Muchar, E., Dispenzieri, A., Wisniewski, B., Palladini, G., Milani, P., Merlini, G., Schonland, S., Veelken, K., Hegenbart, U., Geyer, S. M., Kumar, S. K., Kastiris, E., Dimopoulos, et al  
2022: JCO2200643
- **Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.** *The Journal of experimental medicine*  
Miao, Y. R., Thakkar, K., Cenik, C., Jiang, D., Mizuno, K., Jia, C., Li, C. G., Zhao, H., Diep, A., Xu, Y., Zhang, X. E., Yang, T. T., Liedtke, et al  
2022; 219 (9)
- **Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.** *The New England journal of medicine*  
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Rajee, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., Orlowski, R. Z., Anderson, L. D., Zonder, et al

2022

- **Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., Costello, C., Devarakonda, S., Elsedawy, N., Faiman, M., Garfall, A., Godby, K., Hillengass, et al  
2022; 20 (1): 9-19
- **Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm.** *Frontiers in oncology*  
Fei, F., Liedtke, M., Silva, O.  
2022; 12: 903113
- **Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.** *Leukemia*  
Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., Cornell, R. F., Kang, Y., Umyarova, E., Giri, S., Chhabra, S., Liedtke, M., Callander, et al  
2021
- **Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.** *Clinical lymphoma, myeloma & leukemia*  
Costa, L. J., Lin, Y., Cornell, R. F., Martin, T., Chhabra, S., Usmani, S. Z., Jagannath, S., Callander, N. S., Berdeja, J. G., Kang, Y., Vij, R., Godby, K. N., Malek, et al  
2021
- **A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma**  
Paul, B., Liedtke, M., Monge, J., Chaudhry, M., Rifkin, R., Gandhi, M., Khouri, J., Kin, A., Kovacovics, T., Levy, M., Mohrbacher, A., Schmidt, W., Siegel, et al  
WILEY.2021: S11-S13
- **Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma**  
Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., Godby, K., Bal, S., Cornell, R., Kang, Y., Umyarova, E., Giri, S., Chhabra, et al  
CIG MEDIA GROUP, LP.2021: S148-S149
- **Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.** *Blood advances*  
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., Liedtke, M., Stock, W., Beumer, J. H., Mattison, R. J., Storrick, E., Christner, S. M., Lewis, et al  
2021
- **A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.** *Blood cancer journal*  
Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., Tuchman, S. A., Laubach, J., Gasparetto, C., Chanan-Khan, A., Hertzberg, M., deMario, M., Nueesch, et al  
2021; 11 (9): 149
- **Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.** *American journal of ophthalmology case reports*  
Matsumiya, W., Karaca, I., Ghoraba, H., Akhavanrezayat, A., Mobasserian, A., Hassan, M., Regenold, J., Yasar, C., Liedtke, M., Kitazawa, K., Nguyen, Q. D.  
2021; 23: 101133
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*  
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al  
2021; 5 (16): 3147-3151
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*  
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al  
2021
- **Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.**  
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., Liedtke, M.

LIPPINCOTT WILLIAMS & WILKINS.2021

- **Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.** *Bone marrow transplantation*  
Badar, T., Szabo, A., Litzow, M., Burkart, M., Yurkiewicz, I., Dinner, S., Hefazi, M., Shallis, R. M., Podoltsev, N., Patel, A. A., Curran, E., Wadleigh, M., Balasubramanian, et al  
2021
- **Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.** *Circulation. Heart failure*  
Witteles, R. M., Liedtke, M.  
2021: CIRCHEARTFAILURE120008225
- **Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.** *Blood advances*  
Advani, A. S., Larsen, E., Laumann, K., Luger, S. M., Liedtke, M., Devidas, M., Chen, Z., Yin, J., Foster, M. C., Claxton, D., Coffan, K., Tallman, M. S., Appelbaum, et al  
2021; 5 (2): 504–12
- **Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.** *Blood cancer journal*  
Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., Liedtke, M., Jaccard, A., Wechalekar, A. D., Comenzo, R., Sanchorawala, V., Royer, B., Rosenzweig, et al  
2021; 11 (1): 10
- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*  
Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.  
2021: 1–6
- **Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Jain, N., Kirby, S., Liedtke, et al  
2021; 19 (9): 1079-1109
- **Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.** *Cancer*  
Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D. J., Gokbuget, N., Advani, A. S., O'Brien, S., Liedtke, M., Merchant, A. A., Cassaday, R. D., Wang, T., Zhang, H., Vandendries, et al  
2020
- **Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.** *Blood cancer journal*  
DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhofer, A., Kantarjian, et al  
2020; 10 (8): 81
- **Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.** *Blood advances*  
Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., Aldoss, I., Siebenaller, C., Schultz, E., Hefazi, M., Shallis, R. M., Yurkiewicz, I., Podoltsev, et al  
2020; 4 (10): 2308–16
- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**  
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**  
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.** *Clinical lymphoma, myeloma & leukemia*

- Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., Aldoss, I., Schultz, E., Hefazi, M., Litzow, M. R., Kuo, E., Wang, A., Curran, et al  
2020
- **Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience**  
Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M., Aldoss, I., Sienbenaller, C., Schultz, E., Hefazi, M., Shallis, R., Yurkiewicz, I., Podoltsev, N., Patel, et al  
ELSEVIER SCIENCE INC.2020: S101–S102
  - **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*  
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhert, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.  
2020; 4 (3): 458–66
  - **Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.** *JACC. Heart failure*  
Barrett, C. D., Alexander, K. M., Zhao, H. n., Haddad, F. n., Cheng, P. n., Liao, R. n., Wheeler, M. T., Liedtke, M. n., Schrier, S. n., Arai, S. n., Weisshaar, D. n., Witteles, R. M.  
2020
  - **Single-cell mutational profiling enhances the clinical evaluation of AML MRD.** *Blood advances*  
Ediriwickrema, A. n., Aleshin, A. n., Reiter, J. G., Corces, M. R., Köhnke, T. n., Stafford, M. n., Liedtke, M. n., Medeiros, B. C., Majeti, R. n.  
2020; 4 (5): 943–52
  - **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*  
Lemieux, C. n., Muffy, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al  
2020
  - **Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, et al  
2020; 18 (12): 1685–1717
  - **Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.** *Cancer*  
Badar, T. n., Szabo, A. n., Dinner, S. n., Liedtke, M. n., Burkart, M. n., Shallis, R. M., Yurkiewicz, I. R., Kuo, E. n., Khan, M. A., Balasubramanian, S. n., Yang, J. n., Hefazi, M. n., Podoltsev, et al  
2020
  - **Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH.** *American journal of hematology*  
Cornell, R. n., Hari, P. n., Tang, S. n., Biran, N. n., Callander, N. n., Chari, A. n., Chhabra, S. n., Fiala, M. A., Gahvari, Z. n., Gandhi, U. n., Godby, K. n., Gupta, R. n., Jagannath, et al  
2020
  - **Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.** *Nature biotechnology*  
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., Parks, B., Gars, E., Liedtke, M., Zheng, G. X., Chang, H. Y., Majeti, R., Greenleaf, et al  
2019
  - **Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.** *Leukemia research*  
Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., Martinelli, G., O'Brien, S., Wang, T., Laird, A. D., Vandendries, E., Neuhof, A., Nguyen, et al  
2019; 88: 106283
  - **Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, et al

2019; 17 (10): 1155–65

- **Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)**  
Cornell, R., Parameswaran, H., Tang, S., Barnstead, A., Biran, N., Callander, N., Chari, A., Chhabra, S., Fiala, M., Gahvari, Z., Gandhi, U., Godby, K., Gupta, et al  
CIG MEDIA GROUP. LP.2019: E115–E116
- **Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy** *LEUKEMIA*  
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., Malek, E., Mansour, J., Paul, et al  
2019; 33 (9): 2266–75
- **AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management** *JACC: CARDIOONCOLOGY*  
Witteles, R. M., Liedtke, M.  
2019; 1 (1): 117–30
- **Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients**  
Jha, A., Morgado, I., Lee, D. J., Alexander, K., Tsai, C., Schimmel, K., Ward, J., Witteles, R., Liedtke, M., Liao, R., Dangwal, S.  
LIPPINCOTT WILLIAMS & WILKINS.2019
- **Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study** *CANCER*  
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., O'Brien, S. M., Jabbour, E., Wang, T., White, J., Sleight, B., Vandendries, E., Advani, et al  
2019; 125 (14): 2474–87
- **Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection**  
Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., Majeti, R.  
AMER ASSOC CANCER RESEARCH.2019
- **Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial**  
Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhofer, A., Advani, et al  
NATURE PUBLISHING GROUP.2019: 149–51
- **Grading cardiac response in AL amyloidosis: implications for relapse and survival** *BRITISH JOURNAL OF HAEMATOLOGY*  
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.  
2019; 186 (1): 144–46
- **B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma** *IMMUNOTHERAPY*  
Eckhart, E., Hewitt, R., Liedtke, M.  
2019; 11 (9): 801–11
- **Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma** *NEW ENGLAND JOURNAL OF MEDICINE*  
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., Lam, L., Morgan, R. A., Friedman, et al  
2019; 380 (18): 1726–37
- **A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403** *BLOOD*  
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., Paietta, E., Parker, E., Geyer, et al  
2019; 133 (14): 1548–59
- **Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation**  
Alexander, K., Barrett, C., Dobos, K., Cheng, P., Liao, R., Wheeler, M., Liedtke, M., Weisshaar, D., Witteles, R.  
ELSEVIER SCIENCE INC.2019: S215
- **Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.** *Cancer*

- Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S. M., Jabbour, E., Wang, T., Liang White, J., Sleight, B., Vandendries, E., Advani, et al  
2019
- **Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.** *Leukemia*  
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., Malek, E., Mansour, J., Paul, et al  
2019
  - **Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.** *Best practice & research. Clinical haematology*  
Chung, A., Liedtke, M.  
2019; 32 (1): 54–64
  - **Therapy-related myeloid neoplasms after treatment for plasma-cell disorders** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*  
Chung, A., Liedtke, M.  
2019; 32 (1): 54–64
  - **Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.** *American journal of hematology*  
Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., Martinelli, G., O'Brien, S., White, J. L., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, et al  
2019
  - **Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.** *Blood advances*  
Saygin, C. n., Kishtagari, A. n., Cassaday, R. D., Reizine, N. n., Yurkiewicz, I. n., Liedtke, M. n., Stock, W. n., Larson, R. A., Levine, R. L., Tallman, M. S., Park, J. H., Kerr, C. n., Przychodzen, et al  
2019; 3 (24): 4228–37
  - **Cutaneous plasmablastic plasmacytoma.** *Blood*  
Chung, A. n., Liedtke, M. n.  
2019; 134 (23): 2116
  - **A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.** *JACC. Heart failure*  
Barrett, C. D., Dobos, K. n., Liedtke, M. n., Tuzovic, M. n., Haddad, F. n., Kobayashi, Y. n., Lafayette, R. n., Fowler, M. B., Arai, S. n., Schrier, S. n., Witteles, R. M.  
2019
  - **Grading cardiac response in AL amyloidosis: implications for relapse and survival.** *British journal of haematology*  
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.  
2018
  - **Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis.** *American journal of hematology*  
Gong, C. L., Studdert, A. L., Liedtke, M.  
2018
  - **Antibody-based therapies in patients with acute lymphoblastic leukemia.** *Hematology. American Society of Hematology. Education Program*  
Dinner, S., Liedtke, M.  
2018; 2018 (1): 9–15
  - **A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701**  
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Koltz, J. E., Liedtke, M., Stock, W., Beumer, J. H., Mattison, R. J., Storricks, E., Devine, S., Smith, et al  
AMER SOC HEMATOLOGY.2018
  - **Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse**  
Aleshin, A., Durruthy-Durruthy, R., Corces, M., Stafford, M., Liedtke, M., Medeiros, B. C., Eastburn, D. J., Majeti, R.  
AMER SOC HEMATOLOGY.2018
  - **Antibody-based therapies in patients with acute lymphoblastic leukemia** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*

Dinner, S., Liedtke, M.  
2018; 9-15

- **Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma** *BRITISH JOURNAL OF HAEMATOLOGY*  
Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., Liedtke, M., Chari, A., Smith, S. D., Lebovic, D., Raju, N., Byrne, C., Liao, et al  
2018; 182 (2): 231–44
- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.** *Journal of adolescent and young adult oncology*  
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.  
2018
- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients** *JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY*  
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.  
2018; 7 (5): 579–83
- **Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE** *CANCER*  
Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., O'Brien, S., Wang, T., Paccagnella, M., Sleight, B., Vandendries, E., Advani, A. S., Kantarjian, et al  
2018; 124 (8): 1722–32
- **Clinical implications of gastrointestinal symptoms in systemic amyloidosis** *NEUROGASTROENTEROLOGY AND MOTILITY*  
Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., Nguyen, L. A.  
2018; 30 (4): e13229
- **Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).** *Leukemia research*  
Advani, A. S., Li, H. n., Michaelis, L. C., Medeiros, B. C., Liedtke, M. n., List, A. F., O'Dwyer, K. n., Othus, M. n., Erba, H. P., Appelbaum, F. R.  
2018; 67: 17–20
- **Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia** *DRUG DESIGN DEVELOPMENT AND THERAPY*  
Yurkiewicz, I. R., Muffly, L., Liedtke, M.  
2018; 12: 2293–2300
- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*  
Dinner, S. n., Dunn, T. J., Price, E. n., Coutré, S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.  
2018
- **Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response** *LEUKEMIA & LYMPHOMA*  
Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., Patel, B. J., Sobecks, R., Kalaycio, M., Sekeres, M. A., Mukherjee, S., Gerds, A. T., Hamilton, et al  
2018; 59 (2): 363–71
- **NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, et al  
2018; 16 (1): 11–20
- **Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis**  
Yen, T., Chen, F., Witteles, R., Liedtke, M., Nguyen, L.  
NATURE PUBLISHING GROUP.2017: S240
- **Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow** *CANCER IMMUNOLOGY RESEARCH*

- Hansmann, L., Han, A., Penter, L., Liedtke, M., Davis, M. M.  
2017; 5 (9): 744–54
- **Novel therapeutic approaches for AL amyloid**  
Liedtke, M.  
KARGER.2017: 194
  - **NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY**  
Gertz, M., Comenzo, R. L., Landau, H., Santhorawala, Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, E., Alvarez-Baron, E., et al  
WILEY.2017: 289–90
  - **NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response**  
Liedtke, M., Comenzo, R. L., Landau, H., Santhorawala, V., Weiss, B. M., Zonder, J. A., Schoenland, S. O., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, et al  
KARGER.2017: 34–35
  - **Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis** *BLOOD*  
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., Liedtke, M.  
2017; 130 (7): 900–902
  - **Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study** *BLOOD ADVANCES*  
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., Vandendries, E., Liau, K., Ananthakrishnan, R., Boni, J., Laird, A., Fostvedt, L., Kantarjian, et al  
2017; 1 (15): 1167–80
  - **NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response**  
Liedtke, M., Comenzo, R. L., Landau, H., Santhorawala, V., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, E., Gertz, et al  
WILEY.2017: 441
  - **NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY**  
Liedtke, M., Comenzo, R., Landau, H., Santhorawala, V., Weiss, B., Zonder, J., Walling, J., Kinney, G., Koller, M., Schenk, D. B., Guthrie, S., Liu, E., Gertz, et al  
ELSEVIER SCIENCE INC.2017: 825
  - **Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016**  
Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., Liedtke, M., Paulson, I., Vest, J., Grogan, M.  
TAYLOR & FRANCIS LTD.2017: 165–66
  - **Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, et al  
2017; 15 (2): 230–?
  - **Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.** *Leukemia*  
DeAngelo, D. J., George, T. I., Linder, A. n., Langford, C. n., Perkins, C. n., Ma, J. n., Westervelt, P. n., Merker, J. D., Berube, C. n., Coutre, S. n., Liedtke, M. n., Medeiros, B. n., Sternberg, et al  
2017
  - **Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).** *The American journal of cardiology*  
Tuzovic, M. n., Kobayashi, Y. n., Wheeler, M. n., Barrett, C. n., Liedtke, M. n., Lafayette, R. n., Schrier, S. n., Haddad, F. n., Witteles, R. n.  
2017; 120 (8): 1381–86

- **Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.** *New England journal of medicine*  
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, et al  
2016; 375 (8): 740-753
- **NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study**  
Liedtke, M., Comenzo, R. L., Landau, H., Santhorawala, V., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Gertz, M. A.  
OXFORD UNIV PRESS.2016: 220
- **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*  
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.  
2016; 173 (2): 253-259
- **Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Djulbegovic, B., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, et al  
2016; 14 (4): 389-400
- **First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.** *Journal of clinical oncology*  
Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., Merlini, G., Schönland, S., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, et al  
2016; 34 (10): 1097-1103
- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.** *Leukemia & lymphoma*  
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al  
2016; 57 (3): 609-615
- **Recurrent Subepidermal Blistering Dermatitis Herald Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.** *Clinical lymphoma, myeloma & leukemia*  
Leatham, H. W., Novoa, R., Liedtke, M., Kwong, B. Y.  
2016; 16 (1): e1-5
- **Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.** *Scientific reports*  
Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., Yang, Z., Alagappan, M., Abidi, P., Le, Q., Giaccia, A. J., Denko, N. C., Niwa, et al  
2016; 6: 33353-?
- **Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia**  
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., O'Dwyer, K., Othus, M., Erba, H. P., Appelbaum, F. R.  
AMER SOC HEMATOLOGY.2015
- **Multiple Myeloma, Version 2.2016** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Djulbegovic, B., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, et al  
2015; 13 (11): 1398-1435
- **CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.** *Cell stem cell*  
Iwasaki, M., Liedtke, M., Gentles, A. J., Cleary, M. L.  
2015; 17 (4): 412-421
- **Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma** *CANCER IMMUNOLOGY RESEARCH*  
Hansmann, L., Blum, L., Ju, C., Liedtke, M., Robinson, W. H., Davis, M. M.

2015; 3 (6): 650-660

- **The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NOD001 in patients with AL amyloidosis and cardiac dysfunction.**  
Liedtke, M., Merlini, G., Landau, H., Comenzo, R., Seldin, D. C., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G., Koller, M., Gertz, M. A.  
AMER SOC CLINICAL ONCOLOGY.2015
- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*  
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.  
2015; 15 (3): 650-658
- **A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis**  
Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., Gomes, C. L., Gasparetto, C., Lentzsch, S., Rosenzweig, M., Sanchorawala, V., Smith, D. D., Comenzo, et al  
AMER SOC HEMATOLOGY.2014
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*  
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., Patel, S., Medeiros, B.  
2014; 38 (12): 1441-1445
- **Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.** *American journal of surgical pathology*  
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., Warnke, R. A.  
2014; 38 (9): 1298-1304
- **Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA & LYMPHOMA*  
Dinner, S., Lee, D., Liedtke, M.  
2014; 55 (8): 1715-1724
- **Effects of serum and plasma matrices on multiplex immunoassays.** *Immunologic research*  
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., Maecker, H. T.  
2014; 58 (2-3): 224-233
- **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*  
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.  
2014; 11 (1): 158-162
- **A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.** *Leukemia & lymphoma*  
Patel, S., Liedtke, M., Ngo, D., Medeiros, B. C.  
2013; 54 (10): 2231-2235
- **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*  
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.  
2013; 98 (10): 1593-1599
- **AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R. M., Powers, E. T., Reixach, N., Chan, et al  
2013; 110 (24): 9992-9997
- **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*  
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.  
2013; 161 (3): 367-372
- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*  
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al

2013; 98 (4): 591-596

- **Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., Djulbegovic, B., Faber, E. A., Gasparetto, C., Hernandez-Illizaliturri, F., Huff, C. A., Kassim, A., Krishnan, et al  
2013; 11 (1): 11-17
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.  
AMER SOC HEMATOLOGY.2012
- **Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*  
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al  
2012; 87 (10): 957-960
- **Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.** *Hematology (Amsterdam, Netherlands)*  
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., Liedtke, M.  
2012
- **Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia** *LEUKEMIA*  
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., Bhattacharya, S., Zehnder, J., Liedtke, M., Gotlib, J. R., Coutre, S., Berube, C., Melnick, et al  
2012; 26 (5): 893-901
- **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*  
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.  
2012; 138 (5): 509-511
- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*  
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.  
2012; 31 (3): 325-331
- **The Transcription Factor Encyclopedia** *GENOME BIOLOGY*  
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., Zhang, X. Y., Dickman, C. T., Fulton, D. L., Lim, J. S., Schnabl, J. M., Ramos, O. H., Vasseur-Cognet, et al  
2012; 13 (3)
- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*  
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.  
2012; 97 (1): 30-37
- **Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy** *15th Annual Scientific Meeting of the Heart-Failure-Society-of-America*  
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.  
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2011: S45-S46
- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*  
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.  
2010; 85 (11): 877-881
- **Plasma cell leukemia: concepts and management.** *Expert review of hematology*  
Liedtke, M., Medeiros, B. C.

2010; 3 (5): 543-549

● **Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6** *BLOOD*

Liedtke, M., Ayton, P. M., Somerville, T. C., Smith, K. S., Cleary, M. L.

2010; 116 (1): 63-70

● **Therapeutic targeting of MLL** *BLOOD*

Liedtke, M., Cleary, M. L.

2009; 113 (24): 6061-6068

● **Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma** *LEUKEMIA & LYMPHOMA*

Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., Medeiros, B.

2008; 49 (3): 581-585

● **Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population** *ANNALS OF ONCOLOGY*

Liedtke, M., Hamlin, P. A., Moskowitz, C. H., Zelenetz, A. D.

2006; 17 (6): 909-913

● **Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase** *ONCOGENE*

Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., Kufe, D.

1998; 17 (15): 1889-1892

● **A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV** *BIOCHEMISTRY*

SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., Oelgeschlager, T., Wolfes, H., Peters, F., Pingoud, A.

1992; 31 (20): 4808-4815